AL002 – TREM2 – Alzheimer’s disease
Research suggests that reduction of Triggering Receptor Expressed on Myeloid cells 2 (TREM2) functionality may lead to Alzheimer’s disease and other forms of dementia. AL002 is intended to counteract this decreased functionality by optimizing TREM2 signaling to improve microglia activity. The randomized, controlled Phase 2 study, INVOKE-2, in patients with early Alzheimer’s disease, will enroll approximately 265 participants and assess AL002’s impact on disease progression, as well as changes in multiple fluid and imaging biomarkers. AL002 is being developed in collaboration with AbbVie.